Work

Abstract CT045: Phase 1, open-label, first-in-human study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients (pts) with advanced solid tumors

Year: 2016

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2016-ct045

Authors: Montasser Shaheen, Ben Markman, Michael Carducci, Sara Hurvitz, Daruka Mahadevan, Dusan Kotasek, Oscar Goodman, Erick Gamelin, Vincent Chow, Gloria Juan, Erik Rasmussen, Gregory R. Friberg, Florian D. Vogl, Jayesh Desai

Institutions: University of New Mexico, New Mexico Cancer Center, UNM Comprehensive Cancer Center, Monash Health, Monash University, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of California, Los Angeles, University of Arizona Cancer Center, Comprehensive Cancer Centers of Nevada, Amgen (United States), The Royal Melbourne Hospital

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2505993485

Cites:

Cited by: 1

Related to: 10